Pfizer is looking to expand the indication for its RA drug Xeljanz. The drugmaker announced Monday that it plans to file an sNDA to expand the pill’s label to include moderate-to-severe plaque psoriasis. The company expects to file the request for the twice-a-day medication early next year.
An expanded indication of this sort is not uncommon for Xeljanz’s biologic counterparts, drugs such as AbbVie’s Humira, whose indications include RA, plaque psoriasis and Crohn’s disease. Amgen’s RA shot Enbrel is also approved for plaque psoriasis and juvenile idiopathic arthritis, among other conditions.
